{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:26:42Z","timestamp":1787167602807,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Dermatol Online J"],"published-print":{"date-parts":[[2022]]},"DOI":"10.4103\/idoj.idoj_530_21","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T02:28:31Z","timestamp":1642991311000},"page":"23","source":"Crossref","is-referenced-by-count":11,"title":["The clinical characteristics, putative drugs, and optimal management of 62 patients with stevens-johnson syndrome and\/or toxic epidermal necrolysis: A retrospective observational study"],"prefix":"10.4103","volume":"13","author":[{"given":"VikramK","family":"Mahajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujaya","family":"Manvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KaraninderS","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PushpinderS","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Vashist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabal","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5178.336360-1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens\u2013 Johnson syndrome and toxic epidermal necrolysis","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"key-10.4103\/2229-5178.336360-2","doi-asserted-by":"crossref","first-page":"e45516","DOI":"10.1371\/journal.pone.0045516","article-title":"Recovered patients with Stevens Johson syndrome and toxic epidermal necrolysis maintain long lived IFN-c and sFasL memory response?","author":"Fu","year":"2012","journal-title":"PLoS One"},{"key":"key-10.4103\/2229-5178.336360-3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2332\/allergolint.55.9","article-title":"Toxic epidermal necrolysis and Stevens Johnson syndrome: Our current understanding","author":"French","year":"2006","journal-title":"Allergol Int"},{"key":"key-10.4103\/2229-5178.336360-4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0310057X0703500317","article-title":"Mycoplasma pneumoniae associated with Stevens Johnson syndrome","author":"Mulvey","year":"2007","journal-title":"Anaesth Intensive Care"},{"key":"key-10.4103\/2229-5178.336360-5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","author":"BastujiGarin","year":"1993","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.336360-6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ijd.14493","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective descriptive study","author":"Carrasquillo","year":"2019","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/2229-5178.336360-7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1440-0960.2011.00862.x","article-title":"The management of toxic epidermal necrolysis","author":"Fernando","year":"2012","journal-title":"Australas J Dermatol"},{"key":"key-10.4103\/2229-5178.336360-8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4103\/0378-6323.120751","article-title":"Patch testing in cutaneous adverse drug reactions: Methodology, interpretation and clinical relevance","author":"Mahajan","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.336360-9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"key-10.4103\/2229-5178.336360-10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs.The EuroSCAR-study","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.336360-11","first-page":"269","article-title":"Toxic epidermal necrolysis and Steven-Johnson syndrome in oncologic patients","author":"Gravante","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key-10.4103\/2229-5178.336360-12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens Johnson syndrome and toxic epidermal necrolysis","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"key-10.4103\/2229-5178.336360-13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4103\/0378-6323.191134","article-title":"Guidelines for the management of Stevens\u2013 Johnson syndrome\/toxic epidermal necrolysis: An Indian perspective","author":"Gupta","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.336360-14","first-page":"767","article-title":"Cutaneous adverse drug reactions in hospitalized patients","author":"Lee","year":"2016","journal-title":"Singapore Med J"},{"key":"key-10.4103\/2229-5178.336360-15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/2229-5178.336360-16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4103\/idoj.IDOJ_437_20","article-title":"Factors predicting the outcome of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: A 5-year retrospective study","author":"Thakur","year":"2021","journal-title":"Indian Dermatol Online J","ISSN":"https:\/\/id.crossref.org\/issn\/2229-5178","issn-type":"print"},{"key":"key-10.4103\/2229-5178.336360-17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/ijd.15416","article-title":"A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs)","author":"Singh,","year":"2021","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/2229-5178.336360-18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","article-title":"Epidemiology of hypersensitivity drug reactions","author":"Gomes","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"key-10.4103\/2229-5178.336360-19","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","author":"Mockenhaupt","year":"2005","journal-title":"Neurology"},{"key":"key-10.4103\/2229-5178.336360-20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1528-1167.2006.00423.x","article-title":"Predictors of lamotrigine associated rash","author":"Hirsch","year":"2006","journal-title":"Epilepsia"},{"key":"key-10.4103\/2229-5178.336360-21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4103\/0019-5154.117319","article-title":"Toxic epidermal necrolysis due to concomitant use of lamotrigine and valproic acid","author":"Kaur","year":"2013","journal-title":"Indian J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/2229-5178.336360-22","first-page":"13","article-title":"A study of clinical patterns and causative agents of adverse cutaneous drug reactions","author":"Mahatme","year":"2016","journal-title":"Indian J Drugs Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/2455-3972","issn-type":"print"},{"key":"key-10.4103\/2229-5178.336360-23","first-page":"2042098620905998","article-title":"Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: A database review from 2004 to 2017","author":"Oshikoya","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"key-10.4103\/2229-5178.336360-24","first-page":"391","article-title":"Ethambutol induced toxic epidermal necropysis","author":"Chaudhary","year":"2011","journal-title":"J Assoc Physicians India"},{"key":"key-10.4103\/2229-5178.336360-25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"EuroSCAR Study Group.Allopurinol is the most common cause of Stevens Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.336360-26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","article-title":"Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: Results from the UK General Practice Research Database (GPRD)","author":"Mikuls","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"key-10.4103\/2229-5178.336360-27","first-page":"67","article-title":"Nevirapine-associated Stevens-Johnson syndrome","author":"Warren","year":"1998","journal-title":"Lancet"},{"key":"key-10.4103\/2229-5178.336360-28","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0149-2918(98)80105-7","article-title":"Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection","author":"Pollard","year":"1998","journal-title":"Clin Ther"},{"key":"key-10.4103\/2229-5178.336360-29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00015550310002611","article-title":"Severe cutaneous reactions associated with the use of human immunodeficiency virus medications","author":"Rotunda","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"key-10.4103\/2229-5178.336360-30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40800-015-0019-z","article-title":"A suspected case of Efavirenz-induced Stevens\u2013Johnson syndrome","author":"Paik","year":"2015","journal-title":"Drug Saf Case Rep"},{"key":"key-10.4103\/2229-5178.336360-31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s15010-004-4034-8","article-title":"Efavirenz-associated Stevens-Johnson Syndrome","author":"Colebunders","year":"2004","journal-title":"Infection"},{"key":"key-10.4103\/2229-5178.336360-32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.336360-33","first-page":"398","article-title":"Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: An open uncontrolled study","author":"Mangla","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.336360-34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","author":"AlMutairi","year":"2004","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/2229-5178.336360-35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami experience","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.336360-36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.336360-37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.336360-38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.336360-39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): Experience with high-dose intravenous immunoglobulins and topical conservative approach.A retrospective analysis","author":"Stella","year":"2007","journal-title":"Burns"},{"key":"key-10.4103\/2229-5178.336360-40","first-page":"506","article-title":"Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: A prospective comparative open-labelled study of 36 cases","author":"Jagadeesan","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.336360-41","first-page":"250","article-title":"Role of blood transfusion in the management of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)","author":"Dhar","year":"1998","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.336360-42","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson Syndrome and toxic epidermal necrolysis in United States adults","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.336360-43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.336360-44","first-page":"187","article-title":"Toxic epidermal necrolysis: Part II.Prognosis, sequalae, diagnosis, differential diagnosis, prevention, and treatment","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.336360-45","first-page":"149","article-title":"SCORTEN: A severity-of-illness score for toxic epidermal necrolysis","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.336360-46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.336360-47","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: A multicenter retrospective study of 377 adult patients from the United States","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.336360-48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.BCR.0000216532.71360.9B","article-title":"SCORTEN overestimates mortality in the setting of a standardized treatment protocol","author":"Imahara","year":"2006","journal-title":"J Burn Care Res"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:24:31Z","timestamp":1787163871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_530_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["336360"],"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_530_21","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}